This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dr. Mark Freedman To Join Opexa’s Scientific Advisory Board

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced it has recently added a key international opinion leader to its Scientific Advisory Board. Mark Freedman, M.D., is a professor of medicine in the field of neurology at the University of Ottawa, and director of the Multiple Sclerosis Research Unit at the Ottawa Hospital, General Campus. He will be joining other colleagues of high regard on Opexa’s Scientific Advisory Board: Dawn McGuire, M.D. (Chair), Doug Arnold, M.D., Edward Fox, M.D., Ph.D., Hans-Peter Hartung, M.D., Clyde Markowitz, M.D., Paul O’Connor, M.D., and Arthur Vandenbark, Ph.D.

“It is a distinct pleasure to welcome Dr. Freedman to Opexa’s Scientific Advisory Board,” stated Dr. McGuire, Chair of the SAB. “Dr. Freedman is internationally renowned for his expertise in MS translational research and has been involved in numerous clinical trials in patients with MS. We will benefit greatly from his clinical and scientific insights as we move to the next phase of Tovaxin development for MS.”

“As a neuroimmunologist, I have carefully followed Opexa’s technology for some time and have always been intrigued about this novel approach to treating MS patients,” commented Dr. Freedman. “As a personalized and targeted therapy with an excellent safety profile, Tovaxin may prove to be a differentiated product for the treatment of both Relapsing Remitting and Secondary Progressive MS patients. I look forward to using my knowledge and experience to guide the Company in their efforts to further develop Tovaxin for patients with MS.”

Mark Freedman, M.D. Bio

Dr. Freedman is currently professor of medicine in the field of neurology at the University of Ottawa, as well as director of the Multiple Sclerosis Research Unit at the Ottawa Hospital, General Campus. He holds his specialist certification in Quebec CSPQ and all of Canada FRCP(C) and is a Fellow of the American Academy of Neurology (FAAN).

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,102.86 -60.13 -0.33%
S&P 500 2,117.07 -6.41 -0.30%
NASDAQ 5,087.5440 -19.0490 -0.37%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs